Cancer Vaccines Market: By Type (Therapeutic Cancer Vaccines, Preventive Cancer Vaccine), By Indication (Skin Cancer, Prostate Cancer, Cervical Cancer, Liver Cancer, Others), By Technology (Viral vector and DNA Cancer Vaccine, Conjugate Vaccines, Whole-Cell Cancer Vaccine, Others), By End-User (Adults, Pediatrics) Regional Analysis & Forecast - 2026
- OI-138 |
- Published date: Jun, 2019 |
- Life Sciences & Healthcare |
- 120 Pages
Introduction
Vaccines play a vital part in maintaining the sustainable health of people across various countries thus, they are employed in various regional disease-prevention strategies. The interest for vaccinations has expanded in the course of the most recent couple of years, from the expansion in rate of both viral and bacterial infectious diseases. The vaccine is an antigenic preparation that figures protection against disease. There are different kinds of vaccines and all give security from various living organisms. Vaccinations are controlled to individuals of various age gatherings, which strengthens their immune system throughout a lifetime and offers protection to various sorts of infectious diseases
Market Overview
The Global Cancer Vaccines Market was valued at $ 3.99 bn in 2018 and is forecasted to grow at 8.7% CAGR between 2018 and 2026, resulting in 2026 global sales of $ 13.56 bn. The market is driven by an owing rise in the administration of prophylactic cancer vaccines and new product launches of novel cancer vaccines. However, longer timelines required for manufacturing a single vaccine are expected to restrain the market growth. Moreover, the surge in investments & findings in the development of cancer vaccines is providing ample opportunities for the market
Cancer vaccine on Indication, cervical cancer segment is expected to account for the largest share of the Liquid Handling market due to the increase in the number of people suffering from human papillomavirus (HPV) infections, which causes approximately 70% of cervical cancers globally
Key Developments
- In Dec 2018, Emergent BioSolutions Inc. announced the submission of an application to the U.S. Food and Drug Administration (FDA) for potential emergency use of NuThrax™ (anthrax vaccine adsorbed with CPG 7909 adjuvant)
- In March 2019, Fina Biosolutions’ licensee completes a phase 3 study and enters the world health organization (WHO) registration for Pneumosil®, a 10-valent pneumococcal conjugate vaccine
Segmentation
The Global Cancer Vaccines Market is broadly segmented into Type, Indication, Technology, End-User, and Region
By Type: Therapeutic cancer vaccines, Preventive cancer vaccines
By Indication: Skin cancer, Prostate Cancer, Cervical Cancer, Liver Cancer, Others
By Technology: Viral vector and DNA cancer vaccines, Conjugate Vaccines, Whole-cell cancer vaccines, Inactivated Vaccines, Antigen/adjuvant cancer vaccines, Live Attenuated Vaccines, Recombinant cancer vaccines, Subunit Vaccines, Dendritic cells cancer vaccines
By End-User: Adults, Pediatrics
By Region: North America, Europe, Asia, and the Rest of the World (RoW)
The key players in the Global Cancer Vaccines Market include Sanofi, GSK, Merck, OncBioMune Pharmaceuticals Inc., MaxiVAX, Aduro Biotech Inc., AstraZeneca, Serum Institute of India PVT. Ltd, CSL Limited and Astellas Pharma
The report covers in-depth analysis of the Global Cancer Vaccines Market. The report assesses the market products pipeline by stage of development (early development, pre-clinical, clinical and in approval), By Type (Therapeutic Cancer Vaccines, Preventive Cancer Vaccine), By Indication (Skin Cancer, Prostate Cancer, Cervical Cancer, Liver Cancer, Others), By Technology (Viral vector and DNA cancer vaccine, conjugate vaccines, whole-cell cancer vaccine, others), By End-User (Adults, Pediatrics). In addition, the report includes key insights on other development activities, including (but not limited to) – licensing (In and Out), collaborations, acquisitions, reimbursement, patent, and regulatory designations.
The report includes in-depth company profiles of key players in the Global Cancer Vaccines Market. The company profile includes key information on the overview, financial highlights, product portfolio, business strategies, and key recent developments.
The report highlights information on emerging companies with potentially disruptive technologies and new market entrants.
Scope:
- Provides detailed analysis of the market structure along with forecast of the various segments and sub-segments of the Global Cancer Vaccines Market
- Provides a comparative analysis of key marketed and pipeline products
- Provides key information on players involved in the Global Cancer Vaccines Market
- Provides a complete overview of market segments and the regional outlook of Global Cancer Vaccines Market
- Provides in-depth coverage of key news related to Global Cancer Vaccines Market, including major mergers and acquisitions and product development updates such as clinical trial progression updates and regulatory updates
-
Data Collation (Primary & Secondary)
-
In-house Estimation (Based on proprietary databases and Models)
-
Market Triangulation
-
Forecasting
-
Market-related information is assembled from both primary and secondary sources.
-
Primary sources involved participants from all global stakeholders such as experts from several related industries and suppliers that have been interviewed to obtain and verify critical information as well as to assess prospects of the market. The participants included are CXOs, VPs, and managers. Plus, our in-house industry experts having decades of industry experience contribute their consulting and advisory services.
-
Secondary sources include public sources such as regulatory frameworks, government IT spending, government demographic indicators, industry association statistics, and company publications annual reports press releases along with paid sources such as Factiva, OneSource, Bloomberg among others.
-
Top-down and bottom-up approaches: The overall market size was used in the top-down approach to estimate the sizes of other individual submarkets (mentioned in the market segmentation by product, type of manufacturing, and disease) through percentage splits from secondary and primary research. The bottom-up approach was also implemented (wherever applicable) for data extracted from secondary research to validate the market segment revenues obtained.
